Patent application number | Description | Published |
20080267979 | Anti-Glypican-3 Antibody - An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention. | 10-30-2008 |
20090041770 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. | 02-12-2009 |
20090163699 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 06-25-2009 |
20100204454 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 08-12-2010 |
20100234571 | FC VARIANTS WITH ALTERED BINDING TO FCRN - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234572 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234573 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234574 | Fc Variants with altered binding to FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100234575 | FC VARIANTS WITH ALTERED BINDING TO FCRN - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 09-16-2010 |
20100317834 | IgG Immunoglobulin Variants with Optimized Effector Function - The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. | 12-16-2010 |
20110110928 | FC VARIANTS WITH ALTERED BINDING TO FCRN - The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index. | 05-12-2011 |
20120088905 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index. | 04-12-2012 |
20120225058 | NOVEL IMMUNOGLOBULIN INSERTIONS, DELETIONS, AND SUBSTITUTIONS - An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more FcγRs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide. | 09-06-2012 |
20120258092 | Optimized Fc Variants - The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes. | 10-11-2012 |